Randomized Controlled Trial of a Drug Regimen That Includes Ciprofloxacin for the Treatment of Pulmonary Tuberculosis
The fluoroquinolones are promising new antituberculous agents. A randomized controlled trial of 200 adult patients with sputum smear-positive pulmonary tuberculosis was conducted in Tanzania. Patients received either a trial regimen (HRC) consisting of isoniazid (300 mg), rifampin (600 mg), and cipr...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 1996-05, Vol.22 (5), p.827-833 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 833 |
|---|---|
| container_issue | 5 |
| container_start_page | 827 |
| container_title | Clinical infectious diseases |
| container_volume | 22 |
| creator | N. Kennedy Berger, L. Curram, J. Fox, R. Gutmann, J. G. M. Kisyombe F. I. Ngowi A. R. C. Ramsay A. O. S. Saruni N. Sam Tillotson, G. L. O. Uiso Yates, M. Gillespie, S. H. |
| description | The fluoroquinolones are promising new antituberculous agents. A randomized controlled trial of 200 adult patients with sputum smear-positive pulmonary tuberculosis was conducted in Tanzania. Patients received either a trial regimen (HRC) consisting of isoniazid (300 mg), rifampin (600 mg), and ciprofloxacin (750 mg) or a control regimen (HRZE) consisting of isoniazid (300 mg), rifampin (600 mg), pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg). The 168 evaluable patients all had negative smears and cultures by month 6, but the time to conversion to negativity was longer for the HRC group than for the HRZE group because of the poor response of patients infected with human immunodeficiency virus (HIV) to the HRC regimen. Relapse was more frequent in the HRC group. The sterilizing activity of ciprofloxacin does not appear to be equal to that of the combination of pyrazinamide and ethambutol, but the difference in outcome was significant only among HIV-infected patients. |
| doi_str_mv | 10.1093/clinids/22.5.827 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_78191620</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4459408</jstor_id><sourcerecordid>4459408</sourcerecordid><originalsourceid>FETCH-LOGICAL-j287t-8ef5050ce9c32a84041165830e878d7636b621411aab1357c85b4c25ceaa0cb03</originalsourceid><addsrcrecordid>eNqFkMtLxDAQxoMovu8eFHIQb13zaJr0KOsTBEXW8zJNU82SJpo0oP71Rly8epphvt_3MTMIHVEyo6Tl59pZb_t0zthMzBSTG2iXCi6rRrR0s_REqKpWXO2gvZRWhFCqiNhG20oy1tZkF-Un8H0Y7Zfp8Tz4KQbnSruIFhwOAwZ8GfMLfjIvdjQeL15hwndeu9ybhOf2LYbBhQ_Q1uMhRDy9muI1MBV4-vE_ZjcGD_ETL3Jnos4uJJsO0NYALpnDdd1Hz9dXi_ltdf9wcze_uK9WTMmpUmYQRBBtWs0ZqJrUlDZCcWKUVL1seNM1jJYhQEe5kFqJrtZMaANAdEf4Pjr7zS17vmeTpuVokzbOgTchp6VUtKUN-x-kQqjy7x_wZA3mbjT98i3asVy3XD-06KdrHZIGN0Tw2qY_jBNJWkELdvyLrdIU4p9c16KEKP4NrGePcg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15580930</pqid></control><display><type>article</type><title>Randomized Controlled Trial of a Drug Regimen That Includes Ciprofloxacin for the Treatment of Pulmonary Tuberculosis</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>N. Kennedy ; Berger, L. ; Curram, J. ; Fox, R. ; Gutmann, J. ; G. M. Kisyombe ; F. I. Ngowi ; A. R. C. Ramsay ; A. O. S. Saruni ; N. Sam ; Tillotson, G. ; L. O. Uiso ; Yates, M. ; Gillespie, S. H.</creator><creatorcontrib>N. Kennedy ; Berger, L. ; Curram, J. ; Fox, R. ; Gutmann, J. ; G. M. Kisyombe ; F. I. Ngowi ; A. R. C. Ramsay ; A. O. S. Saruni ; N. Sam ; Tillotson, G. ; L. O. Uiso ; Yates, M. ; Gillespie, S. H.</creatorcontrib><description>The fluoroquinolones are promising new antituberculous agents. A randomized controlled trial of 200 adult patients with sputum smear-positive pulmonary tuberculosis was conducted in Tanzania. Patients received either a trial regimen (HRC) consisting of isoniazid (300 mg), rifampin (600 mg), and ciprofloxacin (750 mg) or a control regimen (HRZE) consisting of isoniazid (300 mg), rifampin (600 mg), pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg). The 168 evaluable patients all had negative smears and cultures by month 6, but the time to conversion to negativity was longer for the HRC group than for the HRZE group because of the poor response of patients infected with human immunodeficiency virus (HIV) to the HRC regimen. Relapse was more frequent in the HRC group. The sterilizing activity of ciprofloxacin does not appear to be equal to that of the combination of pyrazinamide and ethambutol, but the difference in outcome was significant only among HIV-infected patients.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/clinids/22.5.827</identifier><identifier>PMID: 8722940</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: University of Chicago Press</publisher><subject><![CDATA[Adult ; AIDS-Related Opportunistic Infections - drug therapy ; AIDS/HIV ; Anti-Infective Agents - administration & dosage ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antitubercular Agents - administration & dosage ; Antituberculars ; Biological and medical sciences ; Ciprofloxacin - administration & dosage ; Clinical Articles ; Cultural groups ; Ethambutol - administration & dosage ; Female ; Fluoroquinolones ; HIV-1 ; Humans ; Isoniazid - administration & dosage ; Male ; Medical sciences ; Middle Aged ; Mycobacterium tuberculosis ; Pharmacology. Drug treatments ; Pulmonary tuberculosis ; Pyrazinamide - administration & dosage ; Radiology ; Relapse ; Rifampin - administration & dosage ; Sputum ; Sterilization ; Time Factors ; Tuberculosis ; Tuberculosis, Pulmonary - complications ; Tuberculosis, Pulmonary - drug therapy]]></subject><ispartof>Clinical infectious diseases, 1996-05, Vol.22 (5), p.827-833</ispartof><rights>Copyright 1996 The University of Chicago</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4459408$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4459408$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3070951$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8722940$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>N. Kennedy</creatorcontrib><creatorcontrib>Berger, L.</creatorcontrib><creatorcontrib>Curram, J.</creatorcontrib><creatorcontrib>Fox, R.</creatorcontrib><creatorcontrib>Gutmann, J.</creatorcontrib><creatorcontrib>G. M. Kisyombe</creatorcontrib><creatorcontrib>F. I. Ngowi</creatorcontrib><creatorcontrib>A. R. C. Ramsay</creatorcontrib><creatorcontrib>A. O. S. Saruni</creatorcontrib><creatorcontrib>N. Sam</creatorcontrib><creatorcontrib>Tillotson, G.</creatorcontrib><creatorcontrib>L. O. Uiso</creatorcontrib><creatorcontrib>Yates, M.</creatorcontrib><creatorcontrib>Gillespie, S. H.</creatorcontrib><title>Randomized Controlled Trial of a Drug Regimen That Includes Ciprofloxacin for the Treatment of Pulmonary Tuberculosis</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>The fluoroquinolones are promising new antituberculous agents. A randomized controlled trial of 200 adult patients with sputum smear-positive pulmonary tuberculosis was conducted in Tanzania. Patients received either a trial regimen (HRC) consisting of isoniazid (300 mg), rifampin (600 mg), and ciprofloxacin (750 mg) or a control regimen (HRZE) consisting of isoniazid (300 mg), rifampin (600 mg), pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg). The 168 evaluable patients all had negative smears and cultures by month 6, but the time to conversion to negativity was longer for the HRC group than for the HRZE group because of the poor response of patients infected with human immunodeficiency virus (HIV) to the HRC regimen. Relapse was more frequent in the HRC group. The sterilizing activity of ciprofloxacin does not appear to be equal to that of the combination of pyrazinamide and ethambutol, but the difference in outcome was significant only among HIV-infected patients.</description><subject>Adult</subject><subject>AIDS-Related Opportunistic Infections - drug therapy</subject><subject>AIDS/HIV</subject><subject>Anti-Infective Agents - administration & dosage</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antitubercular Agents - administration & dosage</subject><subject>Antituberculars</subject><subject>Biological and medical sciences</subject><subject>Ciprofloxacin - administration & dosage</subject><subject>Clinical Articles</subject><subject>Cultural groups</subject><subject>Ethambutol - administration & dosage</subject><subject>Female</subject><subject>Fluoroquinolones</subject><subject>HIV-1</subject><subject>Humans</subject><subject>Isoniazid - administration & dosage</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mycobacterium tuberculosis</subject><subject>Pharmacology. Drug treatments</subject><subject>Pulmonary tuberculosis</subject><subject>Pyrazinamide - administration & dosage</subject><subject>Radiology</subject><subject>Relapse</subject><subject>Rifampin - administration & dosage</subject><subject>Sputum</subject><subject>Sterilization</subject><subject>Time Factors</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Pulmonary - complications</subject><subject>Tuberculosis, Pulmonary - drug therapy</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtLxDAQxoMovu8eFHIQb13zaJr0KOsTBEXW8zJNU82SJpo0oP71Rly8epphvt_3MTMIHVEyo6Tl59pZb_t0zthMzBSTG2iXCi6rRrR0s_REqKpWXO2gvZRWhFCqiNhG20oy1tZkF-Un8H0Y7Zfp8Tz4KQbnSruIFhwOAwZ8GfMLfjIvdjQeL15hwndeu9ybhOf2LYbBhQ_Q1uMhRDy9muI1MBV4-vE_ZjcGD_ETL3Jnos4uJJsO0NYALpnDdd1Hz9dXi_ltdf9wcze_uK9WTMmpUmYQRBBtWs0ZqJrUlDZCcWKUVL1seNM1jJYhQEe5kFqJrtZMaANAdEf4Pjr7zS17vmeTpuVokzbOgTchp6VUtKUN-x-kQqjy7x_wZA3mbjT98i3asVy3XD-06KdrHZIGN0Tw2qY_jBNJWkELdvyLrdIU4p9c16KEKP4NrGePcg</recordid><startdate>19960501</startdate><enddate>19960501</enddate><creator>N. Kennedy</creator><creator>Berger, L.</creator><creator>Curram, J.</creator><creator>Fox, R.</creator><creator>Gutmann, J.</creator><creator>G. M. Kisyombe</creator><creator>F. I. Ngowi</creator><creator>A. R. C. Ramsay</creator><creator>A. O. S. Saruni</creator><creator>N. Sam</creator><creator>Tillotson, G.</creator><creator>L. O. Uiso</creator><creator>Yates, M.</creator><creator>Gillespie, S. H.</creator><general>University of Chicago Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>19960501</creationdate><title>Randomized Controlled Trial of a Drug Regimen That Includes Ciprofloxacin for the Treatment of Pulmonary Tuberculosis</title><author>N. Kennedy ; Berger, L. ; Curram, J. ; Fox, R. ; Gutmann, J. ; G. M. Kisyombe ; F. I. Ngowi ; A. R. C. Ramsay ; A. O. S. Saruni ; N. Sam ; Tillotson, G. ; L. O. Uiso ; Yates, M. ; Gillespie, S. H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j287t-8ef5050ce9c32a84041165830e878d7636b621411aab1357c85b4c25ceaa0cb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>AIDS-Related Opportunistic Infections - drug therapy</topic><topic>AIDS/HIV</topic><topic>Anti-Infective Agents - administration & dosage</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antitubercular Agents - administration & dosage</topic><topic>Antituberculars</topic><topic>Biological and medical sciences</topic><topic>Ciprofloxacin - administration & dosage</topic><topic>Clinical Articles</topic><topic>Cultural groups</topic><topic>Ethambutol - administration & dosage</topic><topic>Female</topic><topic>Fluoroquinolones</topic><topic>HIV-1</topic><topic>Humans</topic><topic>Isoniazid - administration & dosage</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mycobacterium tuberculosis</topic><topic>Pharmacology. Drug treatments</topic><topic>Pulmonary tuberculosis</topic><topic>Pyrazinamide - administration & dosage</topic><topic>Radiology</topic><topic>Relapse</topic><topic>Rifampin - administration & dosage</topic><topic>Sputum</topic><topic>Sterilization</topic><topic>Time Factors</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Pulmonary - complications</topic><topic>Tuberculosis, Pulmonary - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>N. Kennedy</creatorcontrib><creatorcontrib>Berger, L.</creatorcontrib><creatorcontrib>Curram, J.</creatorcontrib><creatorcontrib>Fox, R.</creatorcontrib><creatorcontrib>Gutmann, J.</creatorcontrib><creatorcontrib>G. M. Kisyombe</creatorcontrib><creatorcontrib>F. I. Ngowi</creatorcontrib><creatorcontrib>A. R. C. Ramsay</creatorcontrib><creatorcontrib>A. O. S. Saruni</creatorcontrib><creatorcontrib>N. Sam</creatorcontrib><creatorcontrib>Tillotson, G.</creatorcontrib><creatorcontrib>L. O. Uiso</creatorcontrib><creatorcontrib>Yates, M.</creatorcontrib><creatorcontrib>Gillespie, S. H.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>N. Kennedy</au><au>Berger, L.</au><au>Curram, J.</au><au>Fox, R.</au><au>Gutmann, J.</au><au>G. M. Kisyombe</au><au>F. I. Ngowi</au><au>A. R. C. Ramsay</au><au>A. O. S. Saruni</au><au>N. Sam</au><au>Tillotson, G.</au><au>L. O. Uiso</au><au>Yates, M.</au><au>Gillespie, S. H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomized Controlled Trial of a Drug Regimen That Includes Ciprofloxacin for the Treatment of Pulmonary Tuberculosis</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>1996-05-01</date><risdate>1996</risdate><volume>22</volume><issue>5</issue><spage>827</spage><epage>833</epage><pages>827-833</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>The fluoroquinolones are promising new antituberculous agents. A randomized controlled trial of 200 adult patients with sputum smear-positive pulmonary tuberculosis was conducted in Tanzania. Patients received either a trial regimen (HRC) consisting of isoniazid (300 mg), rifampin (600 mg), and ciprofloxacin (750 mg) or a control regimen (HRZE) consisting of isoniazid (300 mg), rifampin (600 mg), pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg). The 168 evaluable patients all had negative smears and cultures by month 6, but the time to conversion to negativity was longer for the HRC group than for the HRZE group because of the poor response of patients infected with human immunodeficiency virus (HIV) to the HRC regimen. Relapse was more frequent in the HRC group. The sterilizing activity of ciprofloxacin does not appear to be equal to that of the combination of pyrazinamide and ethambutol, but the difference in outcome was significant only among HIV-infected patients.</abstract><cop>Chicago, IL</cop><pub>University of Chicago Press</pub><pmid>8722940</pmid><doi>10.1093/clinids/22.5.827</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 1996-05, Vol.22 (5), p.827-833 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78191620 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult AIDS-Related Opportunistic Infections - drug therapy AIDS/HIV Anti-Infective Agents - administration & dosage Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Antitubercular Agents - administration & dosage Antituberculars Biological and medical sciences Ciprofloxacin - administration & dosage Clinical Articles Cultural groups Ethambutol - administration & dosage Female Fluoroquinolones HIV-1 Humans Isoniazid - administration & dosage Male Medical sciences Middle Aged Mycobacterium tuberculosis Pharmacology. Drug treatments Pulmonary tuberculosis Pyrazinamide - administration & dosage Radiology Relapse Rifampin - administration & dosage Sputum Sterilization Time Factors Tuberculosis Tuberculosis, Pulmonary - complications Tuberculosis, Pulmonary - drug therapy |
| title | Randomized Controlled Trial of a Drug Regimen That Includes Ciprofloxacin for the Treatment of Pulmonary Tuberculosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A57%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomized%20Controlled%20Trial%20of%20a%20Drug%20Regimen%20That%20Includes%20Ciprofloxacin%20for%20the%20Treatment%20of%20Pulmonary%20Tuberculosis&rft.jtitle=Clinical%20infectious%20diseases&rft.au=N.%20Kennedy&rft.date=1996-05-01&rft.volume=22&rft.issue=5&rft.spage=827&rft.epage=833&rft.pages=827-833&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1093/clinids/22.5.827&rft_dat=%3Cjstor_proqu%3E4459408%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15580930&rft_id=info:pmid/8722940&rft_jstor_id=4459408&rfr_iscdi=true |